Unilever Wellbeing's strategic expansion into the supplement industry, exemplified by the introduction of Grüns, reflects a broader industry shift towards personalized, science-backed health solutions. This shift is driven by consumer expectations for transparency, high-quality ingredients, and clinical evidence, as well as a growing interest in proactive health management. The company's focus on digital engagement and community building, as seen with Nutrafol's 'Shed the Silence' initiative, is reshaping consumer interactions with wellness brands. This approach not only fosters trust but also provides a real-time feedback loop, allowing brands to adapt and improve based on consumer experiences.
Lori Lauersen, Unilever Wellbeing's senior vice president of global R&D, emphasizes the importance of scientific substantiation, noting that 17 clinical trials were conducted across brands in 2025. This commitment to evidence-based products is a cornerstone of the company's innovation strategy, ensuring that each brand, from Olly to Liquid I.V., is backed by rigorous research. The integration of science-backed formulations with convenient, enjoyable formats is a key differentiator, encouraging long-term consistency and proactive health management.
Looking ahead, Lauersen highlights personalization, healthspan, and the growing use of GLP-1 medications as key areas of focus. GLP-1 is not just a trend but a significant indicator of consumer investment in achieving lifestyle and health goals. This trend is creating demand for complementary products that support hydration, nutrient intake, and hair health, further expanding the scope of Unilever Wellbeing's portfolio. The company's strategic investments in digital commerce and scientific research position it to lead the way in the evolving supplement industry, meeting the needs of a health-conscious consumer base that values both efficacy and convenience.
